地西他滨联合阿霉素逆转白血病K562细胞株多药耐药作用观察  

Reversal effect of decitabine and adriamycin on the multidrug resistance of leukemia cell strain K562

作　　者：李静怡[1,2] 邓琦[2] 刘鹏江[2] 赵明峰[2] 李玉明[2] 王学谦[3] 

机构地区：[1]天津医科大学研究生院,天津300070 [2]天津市第一中心医院 [3]天津医院

出　　处：《山东医药》2010年第17期19-21,共3页Shandong Medical Journal

基　　金：天津市卫生局科技项目(05KY10)

摘　　要：目的观察地西他滨(DCA)联合阿霉素(ADR)对白血病K562细胞株多药耐药的逆转作用,探讨其治疗白血病的可行性。方法以不同浓度DCA+ADR处理K562/ADR细胞,用台盼蓝法观察药物对细胞生长曲线的影响,MTT法检测不同浓度DCA与ADR对K562/ADR细胞的杀伤活性,流式细胞技术检测细胞膜P糖蛋白及细胞内ADR浓度。结果 DCA+ADR对白血病K562细胞株多药耐药有明显逆转作用,可降低细胞膜P糖蛋白表达,提高K562耐药细胞株对ADR的敏感性。结论 DCA联合ADR可逆转白血病K562细胞株多药耐药性。Objective To observe the reversal effect of decitabine and adriamycin（ADR） on the multidrug resistance of leukemia cell strain K562 and to explore its feasibility to treat leukemia.Methods K562/ADR cells were treated with different concentrations of decitabine and ADR.The impact of cell growth curve was observed by Trypan blue staining.Killer acticity of K562/ADR cell with different concentrations of decitabine or ADR was determined by MTT assay.The concentrations of P-glycoprotein in cell membrane and of ADR in cells were determined by FCM.Results Obvious reversal effects of DCA＋ADR on multidrug resistance in leukemia cell strain K562 were observed.Decitabine and ADR could decrease the expression of P-glycoprotein in cell membrane,and improve the sensibility of multidrug resistant cell strain K562 to ADR.Conclusions Decitabine and ADR could reverse the multidrug resistance on leukemia cell strain K562.

关 键 词：白血病 地西他滨 阿霉素 K562/ADR细胞 

分 类 号：R733.7[医药卫生—肿瘤]